Tumor-derived exosomes antagonize innate antiviral immunity

Area of Science:

• Immunology
• Molecular Biology
• Oncology

Background:

• Malignancies can impair innate immunity through largely unknown mechanisms.
• Tumor-derived exosomes (TEXs) are implicated in cancer-host interactions.
• Innate antiviral immunity is crucial for host defense against viral infections.

Purpose of the Study:

• To elucidate the mechanisms by which cancers suppress host innate antiviral immunity.
• To identify key molecular players involved in cancer-mediated immune suppression.
• To investigate the role of tumor-derived exosomes (TEXs) and epidermal growth factor receptor (EGFR) in this process.

Main Methods:

• Screening of the human kinome to identify effector kinases in macrophages.
• Utilizing MEKK2-deficient and wild-type mice in experimental tumor implantation models.
• Administering TEXs to mice to assess effects on innate immunity and viral load.
• Investigating the phosphorylation and ubiquitination status of IRF3.

Main Results:

• TEXs transfer activated EGFR to host macrophages, suppressing innate antiviral immunity.
• MEKK2 kinase in macrophages acts as an effector of TEX-delivered EGFR, negatively regulating antiviral response.
• MEKK2-deficient mice exhibited increased resistance to viral infection.
• TEX injection impaired EGFR- and MEKK2-dependent innate immunity, increasing viral load and morbidity.
• MEKK2 phosphorylates IRF3, blocking its function in type I interferon production.

Conclusions:

• Cancer cells can suppress host innate immunity via TEXs delivering activated EGFR to macrophages.
• The EGFR-MEKK2-IRF3 axis is a critical pathway for cancer-mediated immune suppression.
• This mechanism contributes to the immunocompromised state in cancer patients, increasing susceptibility to infections.